ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Prevalence ofFrontiers in microbiology · 2024Pooled it
- The factors associated with mortality and progressive disease of nontuberculous mycobacterial lung disease: a systematic review and meta-analysis.Scientific reports · 2023Pooled it
- Effect of Individual Agents on Time to Culture Conversion inOpen forum infectious diseases · 2025Trial
- First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections.Antimicrobial agents and chemotherapy · 2021Trial
- Gastric Aspirate Isolate Demonstrates Strain-Level Concordance With Sputum Isolate in Nontuberculous Mycobacterial Pulmonary Disease.Open forum infectious diseases · 2026Article
- Clinical analysis and risk factors associated with poor prognosis in nontuberculous mycobacterial infection.Virulence · 2025Article
- Clinical outcomes and adverse events of nontuberculous mycobacterial lung disease treated at an Italian tertiary referral center.Scientific reports · 2025Observational
- Distinct lung microbiota community states are associated with pulmonary nontuberculous mycobacterial disease prognosis.BMC microbiology · 2025Article
- Immunity AgainstVaccines · 2025Article
- Article
- Transcriptional and cytokine signatures of Mycobacterium abscessus complex pulmonary disease during disease progression and treatment.PLoS neglected tropical diseases · 2025Article
- Insights from the European Nontuberculous mycobacterial pulmonary disease PAtient Disease Experience (ENPADE) survey- exploring disease burden and impact.BMC pulmonary medicine · 2025Article
- Epidemiology of nontuberculous mycobacteria in the Finger Lakes region of New York.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Article
- Non-Tuberculous Mycobacteria: Single Center Analyses of Risk Factors, Management and Mortality Outcomes of Adults with HIV.Diagnostics (Basel, Switzerland) · 2024Article
- Intrapulmonary pharmacokinetics of SPR719 following oral administration of SPR720 to healthy volunteers.Antimicrobial agents and chemotherapy · 2024Article
- Assays for AssessingPathogens (Basel, Switzerland) · 2024Article
- Growing from common ground: nontuberculous mycobacteria and bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Nontuberculous Mycobacterial Infection in Wisconsin Adults and Its Relationship to Race and Social Disadvantage.Annals of the American Thoracic Society · 2023Article
- Dimethyl itaconate is effective in host-directed antimicrobial responses against mycobacterial infections through multifaceted innate immune pathways.Cell & bioscience · 2023Article
- Meeting the challenges of NTM-PD from the perspective of the organism and the disease process: innovations in drug development and delivery.Respiratory research · 2022Review
Corrections and comments
- Commented on by
Authors and funding
28 authors at 9 institutions in 1 country.
Funding
Abstract
backgroundThe increasing global prevalence of pulmonary nontuberculous mycobacteria (NTM) disease has called attention to challenges in NTM diagnosis and management. This study was conducted to understand management and outcomes of patients with pulmonary NTM disease at diverse centers across the United States.
methodsWe conducted a 10-year (2005-2015) retrospective study at 7 Vaccine and Treatment Evaluation Units to evaluate pulmonary NTM treatment outcomes in human immunodeficiency virus-negative adults. Demographic and clinical information was abstracted through medical record review. Microbiologic and clinical cure were evaluated using previously defined criteria.
resultsOf 297 patients diagnosed with pulmonary NTM, the most frequent NTM species were Mycobacterium avium-intracellulare complex (83.2%), M. kansasii (7.7%), and M. abscessus (3.4%). Two hundred forty-five (82.5%) patients received treatment, while 45 (15.2%) were followed without treatment. Eighty-six patients had available drug susceptibility results; of these, >40% exhibited resistance to rifampin, ethambutol, or amikacin. Of the 138 patients with adequate outcome data, 78 (56.5%) experienced clinical and/or microbiologic cure. Adherence to the American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) treatment guidelines was significantly more common in patients who were cured (odds ratio, 4.5, 95% confidence interval, 2.0-10.4; P < .001). Overall mortality was 15.7%.
conclusionsDespite ATS/IDSA Guidelines, management of pulmonary NTM disease was heterogeneous and cure rates were relatively low. Further work is required to understand which patients are suitable for monitoring without treatment and the impact of antimicrobial therapy on pulmonary NTM morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.